Anavex Life Sciences

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's disease and Alzheimer's disease) with ongoing late stage Phase 3 studies in Rett syndrome and Alzheimer's disease, respectively.
Ticker:
AVXL
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
ANAVEX®2-73 (blarcamesine)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Anavex Life Sciences Corp.